BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial. This is an ASCO Meeting Abstract ...
Opinion articles provide independent perspectives on key community issues, separate from our newsroom reporting. The writer of the Dec. 31 letter “ Valid predictor” – a response to a Point of View by ...
Many complex disease traits are observed to be associated with single nucleotide polymorphism (SNP) interactions. In testing small-scale SNP–SNP interactions, variable selection procedures in logistic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback